Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Invetech and Biocartis Announce Biomarker Collaboration

Published: Wednesday, April 16, 2014
Last Updated: Wednesday, April 16, 2014
Bookmark and Share
Agreement supporting global development and manufacture of instrument to analyze protein and nucleic acid biomarkers continues multi-year relationship.

Invetech and Biocartis announced a collaboration agreement to support development and manufacture of Evalution™, Biocartis’ advanced multiplex platform for analysis of a broad range of protein and nucleic acid-based biomarkers.

The EvalutionTM platform, designed to support a range of applications in the clinical research and pharmaceutical markets, provides an integrated reaction and detection environment and supports simultaneous analysis of large numbers of analytes per assay. The technology offers real-time visualization of the reaction and data traceability for easy and reliable assay development.

“We first established a collaborative agreement with Biocartis in 2008 when they were a relatively small startup company. Since that time, our team has delivered the full range of our product realization expertise to support their rapid growth and expansion, from project initiation right through to manufacturing. In addition to our instrument development services we have provided Biocartis with guidance in areas including regulatory, sustaining engineering and instrument service. We look forward to continuing our relationship to help them advance and maximize the potential of the EvalutionTM platform in the years ahead,” said David James, Senior Vice President Diagnostics of Invetech.

EvalutionTM is engineered to reduce hands-on time and development complexity, with the potential to streamline procedures for biomarker verification and validation. Currently, Biocartis has multiple scientific collaborations and partnerships in place for the development of novel content on the EvalutionTM platform, targeting development of assays in the fields of oncology, cardiology, neurology, and immunology.

“At every stage in our growth, and our focus on product development and manufacturing, our relationship with Invetech has been marked by a high level of collaboration as well as outstanding responsiveness, ease of communication, and flexibility. We look forward to their contributions to the production and expansion of the EvalutionTMplatform and our efforts to improve data quality, speed to results, and cost-effectiveness in bioassays around the world,” said Paul Ladestein, Managing Director Business Unit Evalution, Biocartis.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Biocartis and VIB Join Forces
Company will develop a new CRC assay for MSI biomarker detection.
Monday, December 09, 2013
Biocartis and Hospital del Mar Join Forces
License agreement to develop diagnostic colon cancer test.
Monday, October 21, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!